|
|
Volumn 30, Issue 4, 2012, Pages 300-301
|
|
Amgen swallows Micromet to BiTE into ALL market
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
B LYMPHOCYTE ANTIGEN;
BLINATUMOMAB;
CARCINOEMBRYONIC ANTIGEN;
CD19 ANTIGEN;
CD22 ANTIGEN;
CD3 ANTIGEN;
HEXAMETAPHOSPHATE SODIUM;
INOTUZUMAB OZOGAMICIN;
MONOCLONAL ANTIBODY;
MOXETUMOMAB PASUDOTOX;
NELARABINE;
PROSTATE SPECIFIC ANTIGEN;
T LYMPHOCYTE RECEPTOR;
ACUTE LYMPHOBLASTIC LEUKEMIA;
CANCER IMMUNOTHERAPY;
CANCER SURVIVAL;
CELL THERAPY;
CYTOKINE RELEASE SYNDROME;
DRUG EFFICACY;
DRUG SAFETY;
HUMAN;
IMMUNOTHERAPY;
MOLECULARLY TARGETED THERAPY;
NEUROTOXICITY;
NONHODGKIN LYMPHOMA;
NOTE;
PRIORITY JOURNAL;
SEIZURE;
T LYMPHOCYTE;
ANTIBODIES, BISPECIFIC;
CLINICAL TRIALS, PHASE II AS TOPIC;
DRUG INDUSTRY;
HUMANS;
IMMUNOTHERAPY;
PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;
HIRUNDINIDAE;
|
|
EID: 84859638865
PISSN: 10870156
EISSN: 15461696
Source Type: Journal
DOI: 10.1038/nbt0412-300c Document Type: Note |
|
Times cited : (2)
|
|
References (0)
|
